We used the same annual baseline event rates (ie, on dual antiplatelet therapy) for death, nonfatal stroke, and systemic embolism as were used in the evidence pro le comparing VKA to aspirin plus clo- pidogrel in the general AF population (Table 6). For the annual risk of nonfatal MI and nonfatal major extracranial bleeding on aspirin plus clopidogrel, we used the rates reported in the clopidogrel arm of the PLATO (Study of Platelet Inhibition and Patient Outcomes) trial, which compared ticagrelor to clopid- ogrel in patients with ACS receiving aspirin.122 The indirect data summarized in Table 12 suggest that triple therapy may be associated with net clinical e562S Antithrombotic Therapy for Atrial Fibrillation Table [Sections Should Triple Therapy Rather Than Dual Antiplatelet Therapy Be Used in Patients With AF After Intracoronary Stent Placement? Quality Assessment Summary of Findings Risk of Bias Inconsistency Indirectness Imprecision Publication Bias Study Event Rates (%) Relative Effect CI) Estimation of Absolute Effects Time Frame No. 